Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry-Reference-Cited by-同舟云学术

Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry

Published:2023-08 Issue: Volume:202 Page:110766
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Paolisso Pasquale^ORCID,Bergamaschi Luca^ORCID,Cesaro Arturo^ORCID,Gallinoro Emanuele,Gragnano Felice^ORCID,Sardu Celestino^ORCID,Mileva Niya,Foà Alberto,Armillotta Matteo^ORCID,Sansonetti Angelo,Amicone Sara,Impellizzeri Andrea,Belmonte Marta^ORCID,Esposito Giuseppe,Morici Nuccia^ORCID,Andrea Oreglia Jacopo,Casella Gianni,Mauro Ciro,Vassilev Dobrin,Galie Nazzareno,Santulli Gaetano^ORCID,Calabrò Paolo,Barbato Emanuele,Marfella Raffaele^ORCID,Pizzi Carmine

Publisher

Elsevier BV

Reference32 articles.

1. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

5. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early prescription of SGLT2i for acute patient care: from current evidence to future directions;Current Problems in Cardiology;2025-08

2. Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials;European Heart Journal - Cardiovascular Pharmacotherapy;2025-06-04

3. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure;Pharmacology & Therapeutics;2025-06

4. The Prognostic Impact of Kidney Dysfunction in Unselected Patients Undergoing Coronary Angiography: In What Subgroups Does Kidney Dysfunction Matter?;Journal of Clinical Medicine;2025-05-27

5. Impact of sodium–glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review;Cardiovascular Diabetology;2025-05-26